EDTA Chelation and Cardiovascular Disease

Beneficial Effects

Beneficial effects of EDTA chelation for people with cardiovascular disease have been reported since the 1950s (Jick & Karsh, 1959).

This has been confirmed in the TACT trial which found chelation patients had a modest reduction in cardiovascular events (Lamas, et al., 2013). A TACT sub-study found significant benefits for people with diabetes (Escolar et al., 2014) – read more detail about that.

Lead and other metals have also been identified as risk factors for cardiovascular disease and reducing blood lead levels through chelation may reduce the risk (Schwartz, 1991; Alissa & Ferns, 2011).

EDTA is well known as an anticoagulant in laboratories. Some evidence suggests there is an increased risk of blood clots that lead to myocardial infarction after insertion of stents, and EDTA chelation may reduce the risk (Chappell, 2007).

Case reports indicate that EDTA chelation may help reduce blood pressure (Jackson, 1992), and improve circulation (Jackson, 1999).

Intravenous Chelation Therapy

EDTA binds with varying affinity to both harmful and essential extracellular metals and facilitates their excretion from the body. It is important to take a multivitamin supplement while having chelation to replace the essential minerals. The multivitamin may also help relieve metal-induced oxidative stress, but additional vitamin C is typically administered with the EDTA for greater benefit.

There are some risks associated with chelation: calcium disodium EDTA may cause renal damage (Flora & Pachauri, 2010) and too-rapid an infusion of disodium EDTA has been linked to fatalities caused by hypocalcemia (Brown, et al., 2006). These risks are managed by slow infusion of EDTA, monitoring renal function and providing extra calcium.

Please contact us to book your appointment.

The information provided here is only for general reference and cannot replace personalised professional medical advice from a doctor. You are welcome to discuss any points during your consultation with our doctors.


  • Alissa EM, Ferns GA. (2011). Heavy metal poisoning and cardiovascular disease. J Toxicol. 2011;870125.
  • Bradberry S, Vale A. (2009). A comparison of sodium calcium edetate (edetate calcium disodium) and succimer (DMSA) in the treatment of inorganic lead poisoning. Clin Toxicol. 47:841-858.
  • Brown MJ, Willis T, Omalu B, et al. (2006). Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005. Pediatrics. 118:e534-e536.
  • Chappell LT. (2007). Should EDTA chelation therapy be used instead of long-term clopidogrel plus aspirin to treat patients at risk from drug-eluting stents? Alt Med Rev. 12:152-158.
  • Escolar E, Lamas GA, Mark DB, et al. (2014). The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes. 7:15–24.
  • Flora SJS, Pachauri V. (2010). Chelation in metal intoxication. Int J Environ Res Public Health. 7:2745-2788.
  • Jackson JA, Riordan HD. (1992). Improvement of essential hypertension after EDTA intravenous infusion treatment. J Orthomol Med. 7:16.
  • Jackson JA, Riordan HD, Schultz M, et al. (1999). Intravenous EDTA Chelation Treatment of a Patient with Atherosclerosis. J Orthomol Med. 14:91-92.
  • Jick S, Karsh R. (1959). The effect of calcium chelation on cardiac arrhythmias and conduction disturbances. Am J Cardiol. 4:287-293.
  • Lamas GA, et al. (2013). Effect of Disodium EDTA Chelation Regimen on Cardiovascular Events in Patients with Previous Myocardial Infarction: the TACT Randomized Trial. The Journal of the American Medical Association 309, 1241-1250.
  • Lewin MR. (1997). Chelation therapy for cardiovascular disease. Review and commentary. Tex Heart Inst J. 24:81-89.
  • Schwartz J. (1991). Lead, blood pressure, and cardiovascular disease in men and women. Environ Health Perspect. 91:71-75.